

RECEIVED

MAY 15 2002

TECH CENTER 1600/2900

(1635)



1600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/945,166A

DATE: 05/07/2002

TIME: 13:18:06

Input Set : A:\Mga00301.app

Output Set: N:\CRF3\05072002\I945166A.raw

ENTERED

3 <110> APPLICANT: ELMALEH, DAVID R.
4 FISCHMAN, ALAN J.
5 BABICH, JOHN W.
7 <120> TITLE OF INVENTION: TARGETED NUCLEIC ACID CONSTRUCTS AND USES RELATED
8 THERETO
10 <130> FILE REFERENCE: MGA-003.01
12 <140> CURRENT APPLICATION NUMBER: 09/945,166A
13 <141> CURRENT FILING DATE: 2001-08-31
15 <160> NUMBER OF SEQ ID NOS: 7
17 <170> SOFTWARE: PatentIn Ver. 2.1
19 <210> SEQ ID NO: 1
20 <211> LENGTH: 26
21 <212> TYPE: PRT
22 <213> ORGANISM: Artificial Sequence
24 <220> FEATURE:
25 <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative
26 peptide
28 <400> SEQUENCE: 1
29 Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys Arg
30 1 5 10 15
32 Arg Gln Arg Arg Pro Pro Gln Gly Ser
33 20 25
36 <210> SEQ ID NO: 2
37 <211> LENGTH: 12
38 <212> TYPE: PRT
39 <213> ORGANISM: Artificial Sequence
41 <220> FEATURE:
42 <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative
43 EGF derived peptide
45 <400> SEQUENCE: 2
46 Cys Met His Ile Glu Ser Leu Asp Ser Tyr Thr Cys
47 1 5 10
50 <210> SEQ ID NO: 3
51 <211> LENGTH: 12
52 <212> TYPE: PRT
53 <213> ORGANISM: Artificial Sequence
55 <220> FEATURE:
56 <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative
57 EGF derived peptide
59 <400> SEQUENCE: 3
60 Cys Met Tyr Ile Glu Ala Leu Asp Lys Tyr Ala Cys
61 1 5 10
64 <210> SEQ ID NO: 4

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/945,166A

DATE: 05/07/2002

TIME: 13:18:06

Input Set : A:\Mga00301.app
Output Set: N:\CRF3\05072002\I945166A.raw

65 <211> LENGTH: 32
66 <212> TYPE: PRT
67 <213> ORGANISM: Artificial Sequence
69 <220> FEATURE:
70 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
71 peptide
73 <220> FEATURE:
74 <221> NAME/KEY: MOD_RES
75 <222> LOCATION: (1)
76 <223> OTHER INFORMATION: Preferably a unique residue, such as Cys or Lys
78 <220> FEATURE:
79 <221> NAME/KEY: MOD_RES
80 <222> LOCATION: (2)..(3)
81 <223> OTHER INFORMATION: Variable amino acid
83 <400> SEQUENCE: 4

W--> 84 Xaa Xaa Xaa Glu Ala Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu Ala
85 1 5 10 15
87 Glu Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu Glu Ala Leu Ala Ala
88 20 25 30
91 <210> SEQ ID NO: 5
92 <211> LENGTH: 8
93 <212> TYPE: PRT
94 <213> ORGANISM: Artificial Sequence
96 <220> FEATURE:
97 <223> OTHER INFORMATION: Description of Artificial Sequence: Illustrative
98 peptide substrate for N-myristoyl transferase
100 <400> SEQUENCE: 5
101 Gly Asn Ala Ala Ala Ala Arg Arg
102 1 5
105 <210> SEQ ID NO: 6
106 <211> LENGTH: 18
107 <212> TYPE: DNA
108 <213> ORGANISM: Artificial Sequence
110 <220> FEATURE:
111 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
112 oligonucleotide
114 <400> SEQUENCE: 6
115 gtgtcggggt ctccgggc 18
118 <210> SEQ ID NO: 7
119 <211> LENGTH: 18
120 <212> TYPE: DNA
121 <213> ORGANISM: Artificial Sequence
123 <220> FEATURE:
124 <223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
125 oligonucleotide
127 <400> SEQUENCE: 7
128 gcccgagac cccgacac 18

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 05/07/2002
PATENT APPLICATION: US/09/945,166A TIME: 13:18:07

Input Set : A:\Mga00301.app
Output Set: N:\CRF3\05072002\I945166A.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:4; Xaa Pos. 1,2,3